Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
P/E ratio for Idorsia Ltd (IDIA.SW)
P/E ratio as of 2023: -1.26
According to Idorsia Ltd's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.26. At the end of 2022 the company had a P/E ratio of -2.88.
P/E ratio history for Idorsia Ltd from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.26 |
| 2022 | -2.88 |
| 2021 | -4.95 |
| 2020 | -8.19 |
| 2019 | -8.05 |
| 2018 | -5.61 |
| 2017 | -206.07 |
| 2016 | -4.85 |